From October 23 to 27, NYU Langone Health experts will join colleagues from around the globe at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Below are notable sessions featuring our faculty and trainees. For the full list of presentations, refer to the conference website.
Saturday, October 24
Rapid Oral Session
1954RO – INCA33890, a TGFβR2xPD-1 Bispecific Antibody, With Standard of Care (SoC) Anticancer Therapies for Microsatellite Stable Colorectal Cancer (MSS CRC)
Co-Author: Kristen Spencer, DO
Time: 9:27–9:32 a.m.
Location: Cadiz Auditorium – NCC
Rapid Oral Session
790RO – Preliminary Clinical Results of QTX3034, an Oral G12D-Preferring KRAS Inhibitor, in Combination with Cetuximab ± mFOLFOX6 in Patients with KRASG12D-Mutated Colorectal Cancer (CRC)
Co-Author: Kristen Spencer, DO
Time: 3:17–3:22 p.m.
Location: Almeria Auditorium – Hall 9
Monday, October 26
Rapid Oral Session
3808RO – Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival from the Phase 3 DeLLphi-304 Trial
Co-Author: Salman R. Punekar, MD
Time: 11:14–11:19 a.m.
Location: Burgos Auditorium – Hall 3
Rapid Oral Session
3137RO – Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Co-Author: Manuel Hidalgo, MD
Time: 2:55–3:00 p.m.
Location: Barcelona Auditorium – Hall 9
